Judith N Steenbergen
Overview
Explore the profile of Judith N Steenbergen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhavnani S, Hammel J, Lakota E, Liolios K, Trang M, Rubino C, et al.
Antimicrob Agents Chemother
. 2024 Jul;
68(9):e0128123.
PMID: 39082883
Pharmacokinetic-pharmacodynamic (PK-PD) relationships for efficacy were evaluated using data from omadacycline-treated patients with acute bacterial skin and skin structure infections (ABSSSI) enrolled in two phase 3 studies. Patients received omadacycline...
2.
Bhavnani S, Hammel J, Lakota E, Trang M, Bader J, Bulik C, et al.
Antimicrob Agents Chemother
. 2023 Mar;
67(4):e0221321.
PMID: 36946741
Omadacycline, a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae, is approved in the United States to treat patients with community-acquired bacterial pneumonia...
3.
Torres A, Garrity-Ryan L, Kirsch C, Steenbergen J, Eckburg P, Das A, et al.
Int J Infect Dis
. 2021 Jan;
104:501-509.
PMID: 33484864
Objective: Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed...
4.
Lakota E, Van Wart S, Trang M, Tzanis E, Bhavnani S, Safir M, et al.
Antimicrob Agents Chemother
. 2020 Apr;
64(7).
PMID: 32340986
Omadacycline, a novel aminomethylcycline antibiotic with activity against Gram-positive and -negative organisms, including tetracycline-resistant pathogens, received FDA approval in October 2018 for the treatment of patients with acute bacterial skin...
5.
VanScoy B, Lakota E, Conde H, McCauley J, Friedrich L, Steenbergen J, et al.
Antimicrob Agents Chemother
. 2020 Apr;
64(6).
PMID: 32284378
Omadacycline is a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including , which is one of the leading causes of community-acquired bacterial pneumonia (CABP). The evaluation of antimicrobial...
6.
ORiordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das A, et al.
Lancet Infect Dis
. 2019 Sep;
19(10):1080-1090.
PMID: 31474458
Background: Pathogen resistance and safety concerns limit oral antibiotic options for the treatment of acute bacterial skin and skin structure infections (ABSSSI). We aimed to compare the efficacy and safety...
7.
Stets R, Popescu M, Gonong J, Mitha I, Nseir W, Madej A, et al.
N Engl J Med
. 2019 Feb;
380(6):517-527.
PMID: 30726692
Background: Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can be administered intravenously or orally, reaches high concentrations in pulmonary tissues and is active against common pathogens that cause community-acquired...
8.
ORiordan W, Green S, Overcash J, Puljiz I, Metallidis S, Gardovskis J, et al.
N Engl J Med
. 2019 Feb;
380(6):528-538.
PMID: 30726689
Background: Acute bacterial skin and skin-structure infections are associated with substantial morbidity and health care costs. Omadacycline, an aminomethylcycline antibiotic that can be administered once daily either orally or intravenously,...
9.
Soon R, Lenhard J, Bulman Z, Holden P, Kelchlin P, Steenbergen J, et al.
Int J Antimicrob Agents
. 2016 Dec;
49(1):25-30.
PMID: 27931793
The proliferation of multidrug-resistant Gram-negative pathogens has been exacerbated by a lack of novel agents in current development by pharmaceutical companies. Ceftolozane/tazobactam was recently approved by the FDA for the...
10.
Armstrong E, Mikulca J, Cloutier D, Bliss C, Steenbergen J
BMC Infect Dis
. 2016 Nov;
16(1):710.
PMID: 27887579
Background: Fluoroquinolones are a guideline-recommended therapy for complicated urinary tract infections, including pyelonephritis. Elevated drug concentrations of fluoroquinolones in the urine and therapy with high-dose levofloxacin are believed to overcome...